Receiving FDA feedback is a critical step in the drug development process, indicating that Virios Therapeutics can now proceed with a clearer regulatory pathway. This news is likely to be viewed positively by investors as it suggests progress in the development of IMC-2, which could lead to future revenue streams if the treatment is successful. The importance is high due to the direct impact on the company's product pipeline, but not at the maximum since clinical and regulatory hurdles still remain. The confidence level reflects the positive nature of the news but acknowledges the uncertainty inherent in drug development.